Gaudium ivf and women health limited IPO Overview
Gaudium ivf and women health limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹165 Cr. The IPO price band is set at ₹75 to ₹79 per share, and retail investors can apply with a minimum investment of ₹14,931 as per IPO guidelines.
The Gaudium ivf and women health limited IPO opens on 20 Feb 2026 and closes on 24 Feb 2026. The IPO allotment is expected to be finalized on 25 Feb 2026, and the equity shares are proposed to be listed on BSE, NSE on 27 Feb 2026.
Investors can refer to the Gaudium ivf and women health limited IPO RHP-DRHP for detailed information. The issue is managed by Sarthi Capital Advisors Pvt.Ltd. as the book running lead manager, while Bigshare Services Pvt Ltd is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About gaudium ivf and women health limited
The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.
The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.
The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Our treatments are designed for various infertility challenges for both genders. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.
The facilities provide a comprehensive range of male infertility treatments, including advanced sperm retrieval techniques.
Competitive Strength
Patient-Centric Approach
Expert team
Using next-gen INTEGRA Ti labs for ICSI.
Highly Technical USG Guided Services
Established central hubs in prime urban locations, including Mumbai, Bangalore, Delhi NCR, and Patna.
Asset Light Business Model
Investment Objective
Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.
General Corporate Purpose
Total